Overview

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia

Status:
Completed
Trial end date:
2020-08-07
Target enrollment:
Participant gender:
Summary
This is a multiple oral dose, randomized, double-blind, placebo-controlled study assessing the safety, tolerability and pharmacokinetics (PK) of SEP-363856 when administered qhs to Japanese subjects with schizophrenia.
Phase:
Phase 1
Details
Lead Sponsor:
Sumitomo Dainippon Pharma Co., Ltd.